David Scott Miller

19PUBLICATIONS
106CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Feb 19, 2026
Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.

Vicky Makker, Nicoletta Colombo, Antonio Casado

|Dec 12, 2025
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).

Brian M Slomovitz, S John Weroha, Wei Deng

|Apr 07, 2025
Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial.

Jung-Min Lee, Austin Miller, Peter G Rose

|Dec 19, 2024
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma.

Daniela E Matei, Danielle M Enserro, Marcus E Randall

|Apr 25, 2024
Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial.

Ann H Klopp, Danielle Enserro, Matthew Powell

|Apr 04, 2024
Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279.

Neil S Horowitz, Wei Deng, Ivy Peterson

Pageof 4

Frequent Collaborators

4 joint publications

David M O'Malley

3 joint publications

Frederick R Ueland

3 joint publications

Vicky Makker

3 joint publications

Bradley J Monk